NCT03601975View on ClinicalTrials.gov

Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

PHASE3UnknownINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

August 27, 2018

Primary Completion Date

July 30, 2020

Study Completion Date

July 30, 2021

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Gemcitabine/Cisplatin

gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle

Trial Locations (1)

510060

RECRUITING

651 Dongfeng Road East, Yuexiu District, Guanzhou, P.R. China, Guangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY